ライフサイエンスコーパス: ventricular tachyarrhythmia

1 s resuscitated cardiac arrest or spontaneous ventricular tachyarrhythmia).

2 ned by a low ejection fraction and inducible ventricular tachyarrhythmia.

3 uring the year before their index episode of ventricular tachyarrhythmia.

4 ing which atrial shock delivery may induce a ventricular tachyarrhythmia.

5 ion and hospitalization for heart failure or ventricular tachyarrhythmia.

6 type 2 (LQT2) and are associated with fatal ventricular tachyarrhythmia.

7 y end point was an ICD shock for adjudicated ventricular tachyarrhythmia.

8 de configuration to treat potentially lethal ventricular tachyarrhythmia.

9 d increase vulnerability to life-threatening ventricular tachyarrhythmia.

10 h or appropriate ICD discharge for sustained ventricular tachyarrhythmia.

11 ed all 12 episodes of spontaneous, sustained ventricular tachyarrhythmia.

12 ed all 12 episodes of spontaneous, sustained ventricular tachyarrhythmia.

13 ased risk of syncope and sudden death due to ventricular tachyarrhythmias.

14 region, which may promote susceptibility to ventricular tachyarrhythmias.

15 ived 701 antiarrhythmic device therapies for ventricular tachyarrhythmias.

16 no O-CKO mice were inducible into sustained ventricular tachyarrhythmias.

17 an increased risk of sudden death caused by ventricular tachyarrhythmias.

18 suppressing alternans and thereby preventing ventricular tachyarrhythmias.

19 thologic phenotype of ischemiainduced lethal ventricular tachyarrhythmias.

20 and rescued transgenic hearts from malignant ventricular tachyarrhythmias.

21 tients receiving a dual-chamber ICD to treat ventricular tachyarrhythmias.

22 sed in the treatment of supraventricular and ventricular tachyarrhythmias.

23 e therapy for management of life-threatening ventricular tachyarrhythmias.

24 extensively used for the acute treatment of ventricular tachyarrhythmias.

25 Recurrent syncope was always associated with ventricular tachyarrhythmias.

26 acterized clinically by an increased risk of ventricular tachyarrhythmias.

27 s cardiac events, including life-threatening ventricular tachyarrhythmias.

28 arization and syncope or sudden death due to ventricular tachyarrhythmias.

29 TS) and may presage the onset of polymorphic ventricular tachyarrhythmias.

30 f aborted sudden cardiac death or refractory ventricular tachyarrhythmias.

31 changes did not correlate with a history of ventricular tachyarrhythmias.

32 ncing the electrophysiological substrate for ventricular tachyarrhythmias.

33 s (p < 0.005) were independent predictors of ventricular tachyarrhythmias.

34 l-cause mortality and appropriate shocks for ventricular tachyarrhythmias.

35 echocardiographic risk factors in predicting ventricular tachyarrhythmias.

36 appropriate ICD shock defined as a shock for ventricular tachyarrhythmias.

37 ined as appropriate ICD therapy or sustained ventricular tachyarrhythmias.

38 with dilated cardiomyopathy at risk of fatal ventricular tachyarrhythmias.

39 lities of electrical activation that promote ventricular tachyarrhythmias.

40 transplantation but continuing proneness to ventricular tachyarrhythmias.

41 between post-CRT-D LVEF and ICD therapy for ventricular tachyarrhythmias.

42 isk of sudden death previously attributed to ventricular tachyarrhythmias.

43 ts with coronary artery disease and unstable ventricular tachyarrhythmias.

44 ilated cardiomyopathy, as well as atrial and ventricular tachyarrhythmias.

45 e progression and a reduction in the risk of ventricular tachyarrhythmias.

46 CM patients with increased susceptibility to ventricular tachyarrhythmias.

47 ands-off periods for shock delivery to treat ventricular tachyarrhythmias.

48 susceptibility to spontaneous and inducible ventricular tachyarrhythmias.

49 uctural heart disease are at higher risk for ventricular tachyarrhythmias.

50 have AP and QT prolongation, and spontaneous ventricular tachyarrhythmias.

51 posite end point (n=22 patients; 19 atrial/2 ventricular tachyarrhythmia, 1 death) included RV LGE pr

52 linical entities comprising these idiopathic ventricular tachyarrhythmias, a few well-defined clinica

53 ls in escape rhythms and bradycardia-related ventricular tachyarrhythmias after AVB in mice.

54 es the incidence, frequency, and duration of ventricular tachyarrhythmias after coronary artery occlu

55 nt reduction in the risk of life-threatening ventricular tachyarrhythmias among patients with NICM.

56 apy will reduce the risk of life-threatening ventricular tachyarrhythmias among patients with nonisch

57 ent of 702 patients with inducible sustained ventricular tachyarrhythmia and 35% of 1394 patients wit

58 enced 21 episodes, with correct detection of ventricular tachyarrhythmia and subsequent shock therapy

59 occurred in 98 patients, representing 32% of ventricular tachyarrhythmias and 76% of those that would

60 by speckle-tracking echocardiography predict ventricular tachyarrhythmias and provide incremental pro

61 ignificantly suppressed electrically induced ventricular tachyarrhythmias and reduced the incidence o

62 dromes, sympathetic stimulation precipitates ventricular tachyarrhythmias and sudden cardiac death ex

63 tation in heart failure have been plagued by ventricular tachyarrhythmias and sudden cardiac death.

64 a genetic disease associated with a risk of ventricular tachyarrhythmias and sudden death, especiall

65 tations in this gene cause susceptibility to ventricular tachyarrhythmias and sudden death.

66 neity that predisposes to the development of ventricular tachyarrhythmias and sudden death.

67 nates in mediating sympathoexcitation during ventricular tachyarrhythmias and that cardiopulmonary ba

68 th neonatal sudden death and, in some cases, ventricular tachyarrhythmias and waxing and waning cardi

69 eases the occurrence of atrial fibrillation, ventricular tachyarrhythmias, and stroke and length of s

70 duce the incidence of myocardial infarction, ventricular tachyarrhythmias, and sudden cardiac death d

71 ur understanding and treatment of idiopathic ventricular tachyarrhythmias, and these advances are the

72 syncope of undetermined origin and inducible ventricular tachyarrhythmias, appropriate implantable ca

73 Ventricular tachyarrhythmias are characteristic of giant

74 ity (<5% that of human heart), and malignant ventricular tachyarrhythmias are infrequent during acute

75 13 (41%) received appropriate therapy for a ventricular tachyarrhythmia at least once in the six-mon

76 gistry demonstrates a high rate of sustained ventricular tachyarrhythmias at 3 months in at-risk pati

77 atients with syncope of undetermined origin, ventricular tachyarrhythmias at electrophysiologic evalu

78 fibrosis on myocardial biopsy and history of ventricular tachyarrhythmias at presentation (P<0.05 for

79 from dogs that either did or did not exhibit ventricular tachyarrhythmias at the time of study were s

80 ility of using upstream therapies to abort a ventricular tachyarrhythmia before its onset.

81 art failure patients to an increased risk of ventricular tachyarrhythmias, but the incidence of cardi

82 The rate of sustained ventricular tachyarrhythmias by 3 months was 3% among pa

83 tients after termination of life-threatening ventricular tachyarrhythmias by an ICD.

84 enic focus in patients with life-threatening ventricular tachyarrhythmias can be curative.

85 Atrial and ventricular tachyarrhythmias can be perpetuated by up-re

86 ed ventricular tachycardia in whom sustained ventricular tachyarrhythmias cannot be induced have a si

87 spite their ability to effectively terminate ventricular tachyarrhythmias, cardiac mortality in patie

88 WTC attack, a total of 14 patients (11%) had ventricular tachyarrhythmias, compared with 5 (3.8%) in

89 modeling, and enhances the risk of malignant ventricular tachyarrhythmias complicating AVB.

90 Patients in whom sustained ventricular tachyarrhythmias could be induced were rando

91 on 29 patients from the Creighton University ventricular tachyarrhythmia database.

92 he ventricles are vulnerable to induction of ventricular tachyarrhythmia during delivery of atrial sh

93 ne phospholipids can induce lethal malignant ventricular tachyarrhythmias during acute cardiac ischem

94 survivors, 10/17 (59%) experienced sustained ventricular tachyarrhythmias during follow-up and 3 rece

95 The mean number of spontaneous nonsustained ventricular tachyarrhythmias during stage 2 and the occu

96 uring stage 2 and the occurrence of ischemic ventricular tachyarrhythmias during stage 3 also were si

97 in functional conduction block and reentrant ventricular tachyarrhythmias during the fixed drive asso

98 termine whether the occurrence of shocks for ventricular tachyarrhythmias during therapy with implant

99 Ventricular tachyarrhythmias eliciting shocks are often

100 ck efficacy was 83.0% for the first clinical ventricular tachyarrhythmia event; there were no differe

101 Premature stimulation induced ventricular tachyarrhythmia/fibrillation >60 seconds in

102 reduces the incidence of inducible sustained ventricular tachyarrhythmia/fibrillation in canine infar

103 1.6%) were treated by the WCD in response to ventricular tachyarrhythmia/fibrillation.

104 ia (VT) is a strong predictor of spontaneous ventricular tachyarrhythmia following ST-segment-elevati

105 ardiac arrest and arrhythmic death caused by ventricular tachyarrhythmias >/=240 per minute was obser

106 onths, conversion of spontaneously occurring ventricular tachyarrhythmias >200 bpm was identical (97.

107 Ventricular tachyarrhythmias had a low positive and rela

108 Using more intervals to detect ventricular tachyarrhythmias has been associated with re

109 le cardioverter-defibrillator (ICD) to treat ventricular tachyarrhythmias have documented atrial tach

110 with a history of myocardial infarction and ventricular tachyarrhythmias have not been clearly defin

111 Giant cell myocarditis presented as nonfatal ventricular tachyarrhythmia in 10 patients and as a fata

112 Torsade de pointes ventricular tachyarrhythmia in the long QT syndrome is a

113 phase is characterized by propensity toward ventricular tachyarrhythmia in the setting of well-prese

114 er lifetime in 166 patients (19%), sustained ventricular tachyarrhythmias in 17 (2%), and permanent p

115 a uniform and pre-specified protocol induced ventricular tachyarrhythmias in 40% of patients: arrhyth

116 There was a total of 120 sustained ventricular tachyarrhythmias in 41 patients, of whom 54%

117 d stimulation (SCS) reduces the incidence of ventricular tachyarrhythmias in experimental models.

118 on at the ionic and molecular levels lead to ventricular tachyarrhythmias in HF are unknown.

119 digital 12-lead ECGs independently predicts ventricular tachyarrhythmias in ICD-eligible cardiomyopa

120 ventricular assist device (LVAD) therapy on ventricular tachyarrhythmias in patients with advanced c

121 lipidemia is associated with greater risk of ventricular tachyarrhythmias in patients with cardiovasc

122 the true frequency of subsequent spontaneous ventricular tachyarrhythmias in the absence of antiarrhy

123 intermediate LGE-SI is a better predictor of ventricular tachyarrhythmias (including nonsustained ven

124 reater likelihood and increased frequency of ventricular tachyarrhythmias (including NSVT) on ambulat

125 The incidence of ventricular tachyarrhythmia, including ventricular fibri

126 of case reports of R-on-T extrasystoles and ventricular tachyarrhythmia induction as a result of biv

127 well as effective shock delivery to convert ventricular tachyarrhythmia into sinus rhythm.

128 long QT syndrome associated with polymorphic ventricular tachyarrhythmia is emphasized.

129 Ventricular tachyarrhythmias long enough to cause implan

130 the trigger mechanisms of the initiation of ventricular tachyarrhythmias may be similar, irrespectiv

131 stimulation elicited infrequent monomorphic ventricular tachyarrhythmias (MVT), and dominant frequen

132 cardioverter-defibrillator interventions for ventricular tachyarrhythmias (n=31), resuscitated out-of

133 ts, most commonly with ICD interventions for ventricular tachyarrhythmias (n=33) or heart transplanta

134 Ventricular tachyarrhythmia occurred in 35% of the patie

135 A total of 1100 episodes of spontaneous ventricular tachyarrhythmias occurred during a mean of 6

136 ion, ischemia, congestive heart failure, and ventricular tachyarrhythmias occurring during the index

137 tachycardia; and inducible, nonsuppressible ventricular tachyarrhythmia on electrophysiologic study

138 Ventricular tachyarrhythmias on Holter electrocardiogram

139 iveness in preventing sudden death caused by ventricular tachyarrhythmia or fibrillation.

140 on-RV outflow tract) per 24 h; and symptoms, ventricular tachyarrhythmias, or attenuated blood pressu

141 d emergencies, including lack of response to ventricular tachyarrhythmias, pacing failure, and multip

142 ifference in the time to first recurrence of ventricular tachyarrhythmia (post hoc analysis) over the

143 Ventricular tachyarrhythmias present a unique set of sti

144 ocardial infarction who are at high risk for ventricular tachyarrhythmia, prophylactic therapy with a

145 nce of spontaneous and inducible polymorphic ventricular tachyarrhythmias (PVTs).

146 ty-three patients with recurrent hypotensive ventricular tachyarrhythmias refractory to lidocaine, pr

147 amiodarone is a relatively safe therapy for ventricular tachyarrhythmias refractory to other medicat

148 y of intravenous amiodarone in patients with ventricular tachyarrhythmias refractory to standard ther

149 associated higher risks for life-threatening ventricular tachyarrhythmias remain poorly understood.

150 Most patients with ventricular tachyarrhythmias resume driving early.

151 The occurrence of ventricular tachyarrhythmias seems to follow circadian,

152 Twelve patients had ventricular tachyarrhythmias: seven had successful thera

153 been assessed as predictors of death due to ventricular tachyarrhythmias/sudden death in patients wi

154 emodynamic benefits, CRT may also ameliorate ventricular tachyarrhythmia susceptibility in HF patient

155 resynchronization therapy's (CRT) impact on ventricular tachyarrhythmia susceptibility in patients w

156 a blinded manner (relative to date) for all ventricular tachyarrhythmias (tachycardia or fibrillatio

157 deceased patients to assess the incidence of ventricular tachyarrhythmias, the occurrence of shocks,

158 with allowing patients with life-threatening ventricular tachyarrhythmias to drive have not been quan

159 ive reports suggest a response of refractory ventricular tachyarrhythmias to intravenous amiodarone,

160 relation of ejection fraction and inducible ventricular tachyarrhythmias to mode of death in all 179

161 r each therapy, we reviewed 1238 episodes of ventricular tachyarrhythmias treated with shock therapy.

162 The occurrence of ventricular tachyarrhythmias triggering ICD therapy in t

163 Although ventricular tachyarrhythmias usually occur in the settin

164 he relationship between RWT and the risk for ventricular tachyarrhythmia (VA) in patients enrolled in

165 Programming of ventricular tachyarrhythmia (ventricular tachycardia [VT

166 r, the relationship between QRSd and risk of ventricular tachyarrhythmias (ventricular tachycardia/ve

167 aventricular conduction delay, and malignant ventricular tachyarrhythmias (ventricular tachycardia/ve

168 A total of 34 ventricular tachyarrhythmia/ventricular fibrillation epi

169 Spontaneous ventricular tachyarrhythmia (VT)/ventricular fibrillatio

170 Spontaneous ventricular tachyarrhythmias (VT) occurred in more than

171 structural heart disease (SHD) and recurrent ventricular tachyarrhythmias (VT).

172 etween TWA and the spontaneous initiation of ventricular tachyarrhythmias (VTA) in humans are unknown

173 d predict the onset of spontaneous sustained ventricular tachyarrhythmias (VTAs) better than previous

174 arly repolarization (ER) characteristics and ventricular tachyarrhythmias (VTAs) in patients with acu

175 the outcomes of heart failure (HF) or death, ventricular tachyarrhythmias (VTAs), and death.

176 eference], 36%-50%, and >50%) on outcomes of ventricular tachyarrhythmias (VTAs), VTA >/=200 bpm, ICD

177 ion therapy (CRT) and the risk of subsequent ventricular tachyarrhythmias (VTAs).

178 can result in Ca(2+) waves, a major cause of ventricular tachyarrhythmias (VTs) and sudden death.

179 Ws, triggered activities, and stress-induced ventricular tachyarrhythmias (VTs) in a mouse model of c

180 r more short-long (S-L) cardiac sequences to ventricular tachyarrhythmias (VTs) in the long QT syndro

181 s associated with an enhanced propensity for ventricular tachyarrhythmias (VTs) under conditions of m

182 larization and the occurrence of polymorphic ventricular tachyarrhythmias (VTs), sometimes with a twi

183 to AP-A that developed LQTS and polymorphic ventricular tachyarrhythmias (VTs).

184 Ventricular tachyarrhythmia was induced 122 times: 2 of

185 in whom postcollapse rhythm was evaluated, a ventricular tachyarrhythmia was observed in 9.

186 First shock efficacy for ventricular tachyarrhythmias was high regardless of base

187 No episodes of ventricular tachyarrhythmia were induced by atrial shock

188 old knockout mice, spontaneous and inducible ventricular tachyarrhythmias were common, occurring in 6

189 hort, ICD interventions for life-threatening ventricular tachyarrhythmias were frequent and highly ef

190 D interventions terminating life-threatening ventricular tachyarrhythmias were frequent.

191 Patients in whom sustained ventricular tachyarrhythmias were induced by programmed

192 tor implantation, but appropriate shocks for ventricular tachyarrhythmias were noted only in a minori

193 al of 704 patients with inducible, sustained ventricular tachyarrhythmias were randomly assigned to t

194 re than 500 ms (an indicator of potential of ventricular tachyarrhythmia) were reported.

195 e electrophysiologic mechanism of atrial and ventricular tachyarrhythmias, whether they are sustained

196 Four episodes were incorrectly classified as ventricular tachyarrhythmia, which led to inappropriate

197 ts in the past 3 decades in the treatment of ventricular tachyarrhythmias with device-based therapy,

198 More than one third of the patients had a ventricular tachyarrhythmia within the last hour of life

199 of protein in wild-type mice), and malignant ventricular tachyarrhythmias within minutes of ischemia.

200 r ICD therapy reduced sudden death caused by ventricular tachyarrhythmias without affecting heart fai